Narcolepsy

A new phase 2 study explores samelisant's potential to treat cataplexy in narcolepsy type 1, promising improved patient outcomes and safety.

Findings from the Jazz DUET study presented at SLEEP 2025 showed that low-sodium oxybate reduced daytime sleepiness and improved sleep parameters in patients with narcolepsy types 1 and 2.

New phase 2 trial data presented at SLEEP 2025 suggest TAK-861 significantly decreased microsleep frequency and delayed onset of first microsleep in individuals with narcolepsy type 1.

A newly presented actigraphy-based algorithm demonstrated high accuracy in detecting daytime naps, offering insights into napping behavior changes in patients with narcolepsy type 1.

Apnimed's AD109 shows promise in treating obstructive sleep apnea, achieving significant results in a landmark Phase 3 trial, paving the way for FDA approval.

A recent interim analysis of a 5-year observational study showed sustained benefit of pitolisant in reducing excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Over a 4-week treatment period, daridorexant outperformed placebo on several subjective sleep and nocturia assessments, while maintaining a good safety and tolerability profile.

The director of sleep medicine at Nemours Children's Health in Florida talked about the growing role of multidisciplinary care and novel therapies in managing pediatric sleep disorders.

Data suggest no significant differences in comorbidity rates in a newly published study, highlighting dosing challenges and treatment patterns in patients receiving immediate-release sodium oxybate.

A recent post hoc analysis of the REST-ON trial reported that once-nightly sodium oxybate did not worsen the apnea-hypopnea index in individuals with narcolepsy with no or mild sleep apnea.

On World Sleep Day, the president of the American Academy of Sleep Medicine discussed the importance of sleep for health, the risks of sleep deprivation, nonpharmacologic strategies to improve sleep, and the need for greater awareness of sleep disorders.

PAP therapy significantly improved cognitive function, particularly executive and psychomotor skills, in patients with Parkinson disease with comorbid obstructive sleep apnea.

A recent analysis identified potential safety concerns associated with pitolisant, sodium oxybate, solriamfetol, and modafinil, highlighting distinct adverse event profiles for each narcolepsy treatment.

Normotensive patients with narcolepsy on sodium oxybate had over 50% of a higher risk of new-onset hypertension or antihypertensive medication use compared with nonusers of the treatment.

Total healthcare costs were 14% higher for patients with potentially inappropriate medication use in the Alzheimer-insomnia cohort, with significant contributions from inpatient care, ambulatory care, and pharmacy costs.

The president and CEO at Project Sleep talked about the foundational role of social connections and peer support in improving quality of life for individuals with narcolepsy. [WATCH TIME: 5 minutes]

Compared with Alzheimer disease, those with behavioral variant FTD demonstrated increased light sleep (N1%) and reduced deep sleep (N3%), alongside altered sleep dynamics, such as higher transitions between N1 sleep and wake states.

Julie Flygare, JD, president and CEO at Project Sleep, discussed the critical role of social connections and peer support in helping individuals with sleep disorders navigate their diagnosis.

Cognitive behavioral therapy for insomnia, a multicomponent psychotherapy, consists of sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.

Recent findings from an analysis showed that sodium oxybate significantly reduced narcolepsy symptoms, including cataplexy and excessive daytime sleepiness, among patients with the sleep disorder.

In a recent survey, key factors associated with perceived support included knowing someone who had the same diagnosis of their sleep disorder, younger age, and marital status.

The neurologist and sleep disorder specialist at Allegheny Health Network discussed the challenges with preventing narcolepsy and the strategies patients can take to improve their overall prognosis. [WATCH TIME: 4 minutes]

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.

The neurologist and sleep disorder specialist at Allegheny Health Network provided an in-depth exploration of the current advancements and future directions in narcolepsy drug development. [WATCH TIME: 3 minutes]

Over the 6-month treatment period, patients saw improvements in cataplexy frequency, excessive daytime sleepiness, cognition, and work productivity with AXS-12.

In a previously completed phase 1 study, the treatment resulted in significant improvements in wakefulness at doses of 1.0 mg and 2.5 mg, prompting a follow-up study.

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital talked about how the recent approval of once-nightly sodium oxybate for pediatric narcolepsy enables more effective and manageable treatment options for children and families.

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital provided her immediate reaction to the approval of a once-nightly sodium oxybate for pediatric narcolepsy. [WATCH TIME: 7 minutes]

Sodium oxybate is the only FDA-approved once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in pediatric patients with narcolepsy.